Merck Sees Strong Q2 Growth Despite Acquisition-Related Charges

Merck & Co., Inc. (NYSE:MRK) reported its Q2 2026 earnings on August 4, with revenue at $16.6 billion, a 4% growth excluding foreign exchange impacts.

The company's oncology portfolio saw strong demand, particularly in earlier-stage cancers and metastatic indications, contributing to the increase in KEYTRUDA sales by 4% to $8.4 billion.

In addition to oncology, Animal Health revenue rose 5% to $1.8 billion, driven by ruminant and poultry products in the Livestock segment.